Conventional Glioblastoma Multiforme
Conventional glioblastoma multiformes most frequently harbor alterations in CDKN2A, PTEN, CDKN2B, TP53, and EGFR .
CDKN2A Loss, CDKN2B Loss, TP53 Mutation, PTEN Mutation, and TP53 Missense are the most common alterations in conventional glioblastoma multiforme .
There are 9 clinical trials for conventional glioblastoma multiforme, of which 8 are open and 1 is completed or closed. Of the trials that contain conventional glioblastoma multiforme as an inclusion criterion, 4 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), and 1 is phase 2 (1 open).
Temozolomide, cannabinol, and g207 are the most common interventions in conventional glioblastoma multiforme clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.